EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non‐target red blood cells of patients with Crohn's disease

Maartje M van de Meeberg iD, Janani Sundaresan, Marry Lin, Gerrit Jansen, Eduard A Struys, Herma H Fidder, Bas Oldenburg, Wout G N Mares, Nofel Mahmmod, Dirk P van Asseldonk, Svend T Rietdijk, Loes H C Nissen and 5 more

Basic & Clinical Pharmacology & Toxicology · 2024

DOI: 10.1111/bcpt.14047 ↗

At a glance

Multizentrische Studie in Basic & Clinical Pharmacology & Toxicology, 2024. Written by Maartje M van de Meeberg and 16 co-authors. Institution: Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Me…. Major MEDLINE topics: Crohn Disease, Erythrocytes, Intestinal Mucosa, Leukocytes, Mononuclear. Cited 3 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Maag Lever Darm Stichting.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Intracellular methotrexate polyglutamates (MTX‐PGs) concentrations are measurable in red blood cells (RBCs) during MTX treatment. MTX‐PG 3 concentrations correlate with efficacy in patients with Crohn's disease (CD). Since RBCs are not involved in pathogenesis of CD and lack extended MTX metabolism, we determined MTX‐PGs accumulation in peripheral blood mononuclear cells (PBMCs: effector cells) and intestinal mucosa (target cells) and compared those with RBCs as a potential more precise biomarker.

Methods

In a multicentre prospective cohort study, blood samples of patients with CD were collected during the first year of MTX therapy. Mucosal biopsies were obtained from non‐inflamed rectum and/or inflamed intestine. MTX‐PGs concentrations in mucosa, PBMCs and RBCs were measured by liquid chromatography–tandem mass spectrometry.

Results

From 80 patients with CD, a total of 27 mucosal biopsies, 9 PBMC and 212 RBC samples were collected. From 12 weeks of MTX therapy onwards, MTX‐PG 3 was the most predominant species (33%) in RBCs. In PBMCs, the distribution was skewed towards MTX‐PG 1 (48%), which accounted for an 18 times higher concentration than in RBCs. Long‐chain MTX‐PGs were highly present in mucosa: 21% of MTX‐PG total was MTX‐PG 5 . MTX‐PG 6 was measurable in all biopsies.

Conclusions

MTX‐PG patterns differ between mucosa, PBMCs and RBCs of patients with CD.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseErythrocytesIntestinal MucosaLeukocytes, MononuclearMethotrexateAdultAgedFemaleHumansMaleMiddle AgedYoung AdultBiomarkersBiopsyChromatography, LiquidPolyglutamic AcidProspective StudiesTandem Mass SpectrometryCohort Studies

Author keywords

Crohn's diseasemethotrexatepharmacokineticstherapeutic drug monitoring

Substances

BiomarkersMethotrexatemethotrexate polyglutamatePolyglutamic Acid

Authors and institutions

  • Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Medical Centre, VU University Amsterdam, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre, VU University Amsterdam, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, Gelderse Vallei Hospital, Ede, The Netherlands.
  • Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands.

ORCID profiles: Maartje M van de Meeberg

Funding

  • Maag Lever Darm Stichting

Cite

APA

van de Meeberg, M. M., Sundaresan, J., Lin, M., Jansen, G., Struys, E. A., Fidder, H. H., Oldenburg, B., Mares, W. G. N., Mahmmod, N., van Asseldonk, D. P., Rietdijk, S. T., Nissen, L. H. C., de Boer, N. K. H., Bouma, G., Ćalasan, M. B., de Jonge, R., & On behalf on the Dutch Initiative on Crohn and Colitis (ICC) (2024). Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non‐target red blood cells of patients with Crohn's disease. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14047

Vancouver

van de Meeberg MM, Sundaresan J, Lin M, Jansen G, Struys EA, Fidder HH, et al. Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non‐target red blood cells of patients with Crohn's disease. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14047

BibTeX
@article{vandeMeeberg2024,
  author = {van de Meeberg, Maartje M and Sundaresan, Janani and Lin, Marry and Jansen, Gerrit and Struys, Eduard A and Fidder, Herma H and Oldenburg, Bas and Mares, Wout G N and Mahmmod, Nofel and van Asseldonk, Dirk P and Rietdijk, Svend T and Nissen, Loes H C and de Boer, Nanne K H and Bouma, Gerd and Ćalasan, Maja Bulatović and de Jonge, Robert and On behalf on the Dutch Initiative on Crohn and Colitis (ICC), On behalf on the Dutch Initiative on Crohn and Colitis (ICC)},
  title = {Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non‐target red blood cells of patients with Crohn's disease},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2024},
  doi = {10.1111/bcpt.14047}
}
Start for free →